NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

ABSTRACT: In the AVALON cohort of relapsed/refractory AML treated with venetoclax plus hypomethylating agents, NPM1 and IDH1/2 mutations showed no significant impact on response or survival. These findings indicate that prognostic models for relapsed AML should consider treatment context rather than baseline mutation status.

SUBMITTER: Vetro C 

PROVIDER: S-EPMC12797279 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature